{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:00:03Z","timestamp":1778587203413,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T00:00:00Z","timestamp":1147132800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1007\/s10495-006-6986-x","type":"journal-article","created":{"date-parts":[[2006,5,14]],"date-time":"2006-05-14T23:29:59Z","timestamp":1147649399000},"page":"1321-1330","source":"Crossref","is-referenced-by-count":27,"title":["Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines*"],"prefix":"10.1007","volume":"11","author":[{"given":"Marco","family":"Rosetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tesei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Ulivi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Vannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Brigliadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dino","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manlio","family":"Bolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wainer","family":"Zoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,5,9]]},"reference":[{"key":"6986_CR1","first-page":"99","volume":"59","author":"DS Michaud","year":"2004","unstructured":"Michaud DS (2004) Epidemiology of pancreatic cancer. Minerva Chir 59:99\u2013111","journal-title":"Minerva Chir"},{"key":"6986_CR2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/jjco\/hyh045","volume":"34","author":"AB Lowenfels","year":"2004","unstructured":"Lowenfels AB, Maisonneuve P (2004) Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 34:238\u2013244","journal-title":"Jpn J Clin Oncol"},{"key":"6986_CR3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(04)01565-7","volume":"5","author":"MJ MacKenzie","year":"2004","unstructured":"MacKenzie MJ (2004) Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 5:541\u2013549","journal-title":"Lancet Oncol"},{"key":"6986_CR4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1444-0903.2004.00658.x","volume":"34","author":"D Goldstein","year":"2004","unstructured":"Goldstein D, Carroll S, Apte M, Keogh G (2004) Modern management of pancreatic carcinoma. Intern Med J 34:475\u2013481","journal-title":"Intern Med J"},{"key":"6986_CR5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","volume":"94","author":"MJ Thun","year":"2002","unstructured":"Thun MJ, Henley SJ, Patrono C (2002) Non steroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issue. J Natl Cancer Inst 94:252\u2013266","journal-title":"J Natl Cancer Inst"},{"key":"6986_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000071364","volume":"37","author":"JA Baron","year":"2003","unstructured":"Baron JA (2003) Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 37:1\u201324","journal-title":"Prog Exp Tumor Res"},{"key":"6986_CR7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jnci\/djh001","volume":"96","author":"ES Schernhammer","year":"2004","unstructured":"Schernhammer ES, Kang JH, Chan AT, et\u00a0al (2004) A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96:22\u201328","journal-title":"J Natl Cancer Inst"},{"key":"6986_CR8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/djh084","volume":"96","author":"EJ Jacobs","year":"2004","unstructured":"Jacobs EJ, Connell CJ, Rodriguez C, Patel AV, Calle EE, Thun MJ (2004) Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 96:524\u2013528","journal-title":"J Natl Cancer Inst"},{"key":"6986_CR9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/carcin\/11.3.393","volume":"11","author":"M Takahashi","year":"1990","unstructured":"Takahashi M, Furukawa F, Toyoda K, et\u00a0al (1990) Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 11:393\u2013395","journal-title":"Carcinogenesis"},{"key":"6986_CR10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00432-002-0365-y","volume":"128","author":"HM Schuller","year":"2002","unstructured":"Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K, Miller MS (2002) The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol 128:525\u2013532","journal-title":"J Cancer Res Clin Oncol"},{"key":"6986_CR11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1091-255X(00)80029-3","volume":"4","author":"RA Perugini","year":"2000","unstructured":"Perugini RA, McDade TP, Vittimberga FJ, Duffy AJ, Callery MP (2000) Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines. J Gastrointest Surg 4:24\u201332","journal-title":"J Gastrointest Surg"},{"key":"6986_CR12","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0022-3565(24)29465-9","volume":"298","author":"MT Yip-Schneider","year":"2001","unstructured":"Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, Marshall MS (2001) Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 298:976\u2013985","journal-title":"J Pharmacol Exp Ther"},{"key":"6986_CR13","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1016\/S0002-9343(98)00275-7","volume":"105","author":"A Soll","year":"1998","unstructured":"Soll A (1998) Pathogenesis of nonsteroidal anti-inflammatory drug-related upper gastrointestinal toxicity. Am J Med 105:10S\u201316S","journal-title":"Am J Med"},{"key":"6986_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0272-6386(12)80155-7","volume":"24","author":"M Segasothy","year":"1994","unstructured":"Segasothy M, Samad SA, Zulfigar A, Bennett WM (1994) Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 24:17\u201324","journal-title":"Am J Kidney Dis"},{"key":"6986_CR15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1053\/gast.2003.50096","volume":"124","author":"S Fiorucci","year":"2003","unstructured":"Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A (2003) Gastrointestinal safety of NO-aspirin (NCX 4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124:600\u2013607","journal-title":"Gastroenterology"},{"key":"6986_CR16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1053\/j.gastro.2003.11.046","volume":"126","author":"V Shah","year":"2004","unstructured":"Shah V, Lyford G, Gores G, Farrugia G (2004) Nitric oxide in gastrointestinal health and disease. Gastroenterology 126:903\u2013913","journal-title":"Gastroenterology"},{"key":"6986_CR17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/pros.20081","volume":"61","author":"E Huguenin","year":"2004","unstructured":"Huguenin E, Huguenin S, Fleury-Feith J, et\u00a0al (2004) Nitrosulindac (NCX 1102): A new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines. Prostate 61:132\u2013141","journal-title":"Prostate"},{"key":"6986_CR18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.molmed.2004.05.004","volume":"10","author":"B Rigas","year":"2004","unstructured":"Rigas B, Kashfi K (2004) Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 10:324\u2013330","journal-title":"Trends Mol Med"},{"key":"6986_CR19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1535-7163.291.3.3","volume":"3","author":"E Huguenin","year":"2004","unstructured":"Huguenin E, Vacherot F, Kheuang L, et\u00a0al (2004) Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines. Mol Cancer Ther 3:291\u2013298","journal-title":"Mol Cancer Ther"},{"key":"6986_CR20","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1124\/jpet.102.042754","volume":"303","author":"K Kashfi","year":"2002","unstructured":"Kashfi K, Ryan Y, Qiao LL, et\u00a0al (2002) Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther 303:1273\u20131282","journal-title":"J Pharmacol Exp Ther"},{"key":"6986_CR21","first-page":"1297","volume":"22","author":"A Tesei","year":"2003","unstructured":"Tesei A, Ricotti L, Ulivi P, Medri L, Amadori D, Zoli W (2003) NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. Int J Oncol 22:1297\u20131302","journal-title":"Int J Oncol"},{"key":"6986_CR22","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"82","author":"P Skehan","year":"1990","unstructured":"Skehan P, Storeng R, Scudiero D, et\u00a0al (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107\u20131112","journal-title":"J Natl Cancer Inst"},{"key":"6986_CR23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","volume":"83","author":"A Monks","year":"1991","unstructured":"Monks A, Scudiero D, Skehan P, et\u00a0al (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757\u2013766","journal-title":"J Natl Cancer Inst"},{"key":"6986_CR24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10495-005-0619-7","volume":"10","author":"F Fabbri","year":"2005","unstructured":"Fabbri F, Brigliadori G, Ulivi P, et\u00a0al (2005) Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells. Apoptosis 10:1095\u20131103","journal-title":"Apoptosis"},{"key":"6986_CR25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1479-5876-3-7","volume":"3","author":"A Tesei","year":"2005","unstructured":"Tesei A, Ulivi P, Fabbri F, et\u00a0al (2005) In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. J Transl Med 3:7","journal-title":"J Transl Med"},{"key":"6986_CR26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1247\/csf.24.451","volume":"24","author":"M Nakata","year":"1999","unstructured":"Nakata M, Uto N, Maruyama I, Yada T (1999) Nitric oxide-induced apoptosis via Ca2+ dependent process in the pancreatic \u03b2-cell line MIN6. Cell Struct Funct 24:451\u2013455","journal-title":"Cell Struct Funct"},{"key":"6986_CR27","first-page":"1297","volume":"22","author":"A Tesei","year":"2003","unstructured":"Tesei A, Ricotti L, Ulivi P, Medri L, Amadori D, Zoli W (2003) NCX 4016, a nitric oxide-releasing aspirin derivate, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. Int J Oncol 22:1297\u20131302","journal-title":"Int J Oncol"},{"key":"6986_CR28","first-page":"83-91","volume":"341","author":"IH Chae","year":"2004","unstructured":"Chae IH, Park KW, Kim HS, Oh BH (2004) Nitric oxide-induced apoptosis is mediated by Bax\/Bcl-2 gene expression, transition of Cytochrome C, and activation of caspase-3 in rat vascular smooth muscle cells. Clin Chim Acta 341:83-91","journal-title":"Clin Chim Acta"},{"key":"6986_CR29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/15216540310001639652","volume":"55","author":"H Viera","year":"2003","unstructured":"Viera H, Kroemer G (2003) Mitochondria as targets of apoptosis regulation by nitric oxide. IUBMB Life 55:613\u2013616","journal-title":"IUBMB Life"},{"key":"6986_CR30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0736-0266(01)00086-9","volume":"20","author":"RM Chen","year":"2002","unstructured":"Chen RM, Liu HC, Lin YL, Jean WC, Chen JS, Wang JH (2002) Nitric oxide induces osteoblast apoptosis through the de novo synthesis of Bax protein. J Orthop Res 20:295\u2013302","journal-title":"J Orthop Res"},{"key":"6986_CR31","first-page":"109","volume":"16","author":"V Umancky","year":"2000","unstructured":"Umancky V, Ushmorov A, Ratter F, et\u00a0al (2000) Nitric oxide-mediated apoptosis in human breast cancer cells changes in mitochondrial function and is independent of CD95(APO-1\/fas). Int J Oncol 16:109\u2013117","journal-title":"Int J Oncol"},{"key":"6986_CR32","first-page":"5470","volume":"63","author":"S Pervin","year":"2003","unstructured":"Pervin S, Singh R, Chaundhuri G (2003) Nitric-oxide-induced Bax integration into the mitochondrial membrane commits MDA-MB-468 Cells to apoptosis: essential role of Akt. Cancer Res 63:5470\u20135479","journal-title":"Cancer Res"},{"key":"6986_CR33","first-page":"4356","volume":"59","author":"MA Molina","year":"1999","unstructured":"Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59:4356\u20134362","journal-title":"Cancer Res"},{"key":"6986_CR34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1096\/fasebj.11.11.9285487","volume":"11","author":"A Von Knethen","year":"1997","unstructured":"Von Knethen A, Brune B (1997) Cyclooxygenase-2: an essential regulator of NO-mediated apoptosis. FASEB J 11:887\u2013895","journal-title":"FASEB J"},{"key":"6986_CR35","first-page":"6323","volume":"62","author":"Y Sun","year":"2002","unstructured":"Sun Y, Tang XM, Half E, Tien Kuo M, Sinicrope FA (2002) Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome C-dependent apoptotic pathway in human colon cancer cells. Cancer Res 62:6323\u20136328","journal-title":"Cancer Res"},{"key":"6986_CR36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0014-2999(98)00274-X","volume":"351","author":"B Brune","year":"1998","unstructured":"Brune B, von Knethen A, Sandau KB (1998) Nitric oxide and its role in apoptosis. Eur J Pharmacol 351:261\u2013272","journal-title":"Eur J Pharmacol"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-006-6986-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10495-006-6986-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-006-6986-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T23:53:46Z","timestamp":1736380426000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10495-006-6986-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,9]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["6986"],"URL":"https:\/\/doi.org\/10.1007\/s10495-006-6986-x","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,9]]}}}